What is Lexeo Therapeutics, Inc. Common Stock's Market Cap?

Lexeo Therapeutics, Inc. Common Stock's Market Cap is $229.7M, based on as-reported figures from SEC (XBRL) filings.

What is Lexeo Therapeutics, Inc. Common Stock's Enterprise Value?

Lexeo Therapeutics, Inc. Common Stock's Enterprise Value is $137.5M, based on as-reported figures from SEC (XBRL) filings.

What is Lexeo Therapeutics, Inc. Common Stock's EV / EBITDA?

Lexeo Therapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.

What is Lexeo Therapeutics, Inc. Common Stock's Net Income (TTM)?

Lexeo Therapeutics, Inc. Common Stock's Net Income (TTM) is -$87.3M, based on as-reported figures from SEC (XBRL) filings.

What is Lexeo Therapeutics, Inc. Common Stock's EBITDA?

Lexeo Therapeutics, Inc. Common Stock's EBITDA is -$94.8M, based on as-reported figures from SEC (XBRL) filings.

What is Lexeo Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?

Lexeo Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -1.06, based on as-reported figures from SEC (XBRL) filings.

What is Lexeo Therapeutics, Inc. Common Stock's Net Debt?

Lexeo Therapeutics, Inc. Common Stock's Net Debt is -$92.3M, based on as-reported figures from SEC (XBRL) filings.

AKYLA/ Financials

Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Lexeo Therapeutics, Inc. Common Stock

XNAS · usd

SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

FIGI BBG00YB1C8N4

2.80▼ 0.09 (-3.11%)

As of 2026-10-23

Price / Volume

Valuation

Market Cap
Enterprise Value
Trailing P/E: —
Price / Sales: —
EV / Revenue: —
EV / EBITDA

Financial Highlights

Revenue (TTM): —
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin: —
Net Debt

Trading Information

Previous Close: 2.89
Day's Range: 2.73 – 2.97
52-Week Range: 2.55 – 10.99
Volume: 619.4K
Avg Volume: 1.8M

Share Statistics

Shares Outstanding
Employees: 59
Exchange: XNAS
Listed: 2023-11-03

Share count as of August 10, 2026

Lexeo Therapeutics, Inc. Common Stock (LXEO) Financial Statements

View

Income Statement

Detail

Standard

Period

Quarterly

Loading Income Statement…

Key questions about Lexeo Therapeutics, Inc. Common Stock (LXEO)

What is Lexeo Therapeutics, Inc. Common Stock's Market Cap?: Lexeo Therapeutics, Inc. Common Stock's Market Cap is $229.7M, based on as-reported figures from SEC (XBRL) filings.
What is Lexeo Therapeutics, Inc. Common Stock's Enterprise Value?: Lexeo Therapeutics, Inc. Common Stock's Enterprise Value is $137.5M, based on as-reported figures from SEC (XBRL) filings.
What is Lexeo Therapeutics, Inc. Common Stock's EV / EBITDA?: Lexeo Therapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Lexeo Therapeutics, Inc. Common Stock's Net Income (TTM)?: Lexeo Therapeutics, Inc. Common Stock's Net Income (TTM) is -$87.3M, based on as-reported figures from SEC (XBRL) filings.
What is Lexeo Therapeutics, Inc. Common Stock's EBITDA?: Lexeo Therapeutics, Inc. Common Stock's EBITDA is -$94.8M, based on as-reported figures from SEC (XBRL) filings.
What is Lexeo Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?: Lexeo Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -1.06, based on as-reported figures from SEC (XBRL) filings.
What is Lexeo Therapeutics, Inc. Common Stock's Net Debt?: Lexeo Therapeutics, Inc. Common Stock's Net Debt is -$92.3M, based on as-reported figures from SEC (XBRL) filings.

Akyla / Financials · LXEOAs-filed SEC (XBRL) data